S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

$49.12
+0.01 (+0.02%)
(As of 02/23/2024 ET)
Today's Range
$49.01
$49.97
50-Day Range
$31.97
$52.38
52-Week Range
$18.00
$53.78
Volume
455,865 shs
Average Volume
1.25 million shs
Market Capitalization
$3.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.67

SpringWorks Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.4% Upside
$56.67 Price Target
Short Interest
Bearish
16.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of SpringWorks Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$751,500 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.03) to ($4.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.20 out of 5 stars

Medical Sector

767th out of 939 stocks

Biological Products, Except Diagnostic Industry

137th out of 159 stocks


SWTX stock logo

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Stock Price History

SWTX Stock News Headlines

Claim $10,000 In FREE silver In 2024
Thanks to forgotten 50-year-old legislation, often ignored by investment advisors, gold bugs, and silver hounds…You can now collect $10,000 or more in free silver. Millions of Americans know NOTHING about this…Because it exploits a “glitch” in the IRS tax code that helps protect your retirement...While paying ZERO TAXES & PENALTIES to do it. That’s why you need to see this NOW.
SpringWorks Therapeutics Inc Insider Sells Company Shares
Claim $10,000 In FREE silver In 2024
Thanks to forgotten 50-year-old legislation, often ignored by investment advisors, gold bugs, and silver hounds…You can now collect $10,000 or more in free silver. Millions of Americans know NOTHING about this…Because it exploits a “glitch” in the IRS tax code that helps protect your retirement...While paying ZERO TAXES & PENALTIES to do it. That’s why you need to see this NOW.
Wall Street Analysts Are Bullish on Top Healthcare Picks
SpringWorks Therapeutics Inc Ordinary Shares
Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving
See More Headlines
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/02/2023
Today
2/23/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SWTX
Fax
N/A
Employees
227
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$56.67
High Stock Price Target
$75.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+15.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-277,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.95 per share

Miscellaneous

Free Float
57,929,000
Market Cap
$3.07 billion
Optionable
Optionable
Beta
0.82

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Saqib Islam J.D. (Age 54)
    CEO & Director
    Comp: $1.26M
  • Mr. Francis I. Perier Jr. (Age 64)
    M.B.A., Chief Financial Officer
    Comp: $710.6k
  • Dr. Badreddin Edris Ph.D. (Age 37)
    Chief Operating Officer
    Comp: $998.61k
  • Mr. Bhavesh Ashar (Age 58)
    Chief Commercial Officer
    Comp: $729.62k
  • Mr. Michael P. Nofi (Age 53)
    Chief Accounting Officer
  • Mr. Tai-An Lin Ph.D.
    Chief Scientific Officer
  • Ms. Kim Diamond
    Vice President of Communications & Investor Relations
  • Mr. Herschel S. Weinstein J.D. (Age 68)
    General Counsel & Secretary
    Comp: $568.64k
  • Mr. Daniel J. PichlMr. Daniel J. Pichl (Age 41)
    Chief People Officer
    Comp: $428.51k
  • Dr. James Cassidy M.D. (Age 65)
    Ph.D., Chief Medical Officer














SWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings
or view top-rated stocks.

What is SpringWorks Therapeutics' stock price target for 2024?

6 analysts have issued 12 month target prices for SpringWorks Therapeutics' stock. Their SWTX share price targets range from $45.00 to $75.00. On average, they predict the company's stock price to reach $56.67 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts price targets for SWTX
or view top-rated stocks among Wall Street analysts.

How have SWTX shares performed in 2024?

SpringWorks Therapeutics' stock was trading at $36.50 at the beginning of the year. Since then, SWTX stock has increased by 34.6% and is now trading at $49.12.
View the best growth stocks for 2024 here
.

When is SpringWorks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SWTX earnings forecast
.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($1.25) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.01. During the same quarter in the prior year, the company earned ($1.41) EPS.

What ETFs hold SpringWorks Therapeutics' stock?
What other stocks do shareholders of SpringWorks Therapeutics own?
When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.65%), Price T Rowe Associates Inc. MD (4.44%), Price T Rowe Associates Inc. MD (4.44%), Point72 Asset Management L.P. (3.46%), Dimensional Fund Advisors LP (1.55%) and Fiera Capital Corp (1.43%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto.
View institutional ownership trends
.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does SpringWorks Therapeutics have any subsidiaries?
The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..
Read More
This page (NASDAQ:SWTX) was last updated on 2/23/2024 by MarketBeat.com Staff